GlassScriptPhysician profile
Logan Hardin
NPI 1891235289
$5,273.69
in general payments reported to CMS, 2019-2025
30 companies · $696 in 2025
The $696 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.27 · 2020: $197 · 2021: $746 · 2022: $846 · 2023: $1,445 · 2024: $1,291 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,371 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,370.65 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,092.02 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $945.60 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $443.00 | 2022-2025 | Rexulti |
| Astellas Pharma US INC | $376.60 | 2023-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $339.13 | 2021-2025 | |
| Amgen INC. | $298.65 | 2020-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $268.36 | 2020-2024 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $238.33 | 2021-2025 | |
| Glaxosmithkline, LLC. | $181.95 | 2023-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $154.08 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $152.97 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.06 | 2020-2024 | Synjardy, Jardiance |
| Merck Sharp & Dohme LLC | $131.31 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $99.48 | 2022-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.18 | 2023-2025 | Xifaxan, Trulance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $63.56 | 2020-2022 | |
| Dynavax Technologies Corporation | $43.39 | 2024-2025 | Heplisav-B |
| Kowa Pharmaceuticals America, INC. | $42.42 | 2022 | |
| Corcept Therapeutics | $24.65 | 2024 | Korlym |
| Inspire Medical Systems, INC. | $23.68 | 2023 | Inspire |
| Gilead Sciences, INC. | $17.33 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.79 | 2025 | Caplyta |
| Shield Therapeutics INC | $15.33 | 2023 | Accrufer |
| Alexion Pharmaceuticals, INC. | $15.17 | 2022 | |
| Ibsa Pharma INC. | $15.16 | 2025 | Tirosint, Licart, Flector |
| Phathom Pharmaceuticals, INC. | $14.16 | 2025 | Voquezna |
| Medtronic, INC. | $13.97 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $12.89 | 2022 | |
| Amarin Pharma, INC. | $12.52 | 2021 | |
| Dexcom, INC. | $11.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Logan Hardin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.